Global Fund Signs Letter of Intent with Pfizer for Oral COVID-19 Treatment

The Global Fund has signed a letter of intent with Pfizer for the procurement of up to 6 million treatment courses of the new oral antiviral medicine nirmatrelvir/ritonavir, sold under the name PAXLOVID™, in 2022-2023.

Related Keywords

Geneva ,Genè ,Switzerland ,United States ,Philippe Duneton ,Peter Sands ,Pfizer ,Global Fund ,Global Fund Signs Letter Of Intent ,Foundation For Innovative New Diagnostics ,Health Systems Response Connector ,Global Fund Signs Letter ,Executive Director ,Unitaid Executive Director Dr Philippe ,Second Global ,Innovative New Diagnostics ,Diagnostics Pillar ,Therapeutics Pillar ,Health Systems ,Signs ,Letter Of Intent ,Oral Covid 19 Treatment ,